Phathom Pharmaceuticals, Inc. Property, Plant, Equpment (Net)

Property, Plant, Equpment (Net) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Property, Plant, Equpment (Net) growth rates and interactive chart. Property, plant, and equipment (aslo called PP&E) are a company's physical or tangible long-term assets that typically have a life of more than one year. Examples of PP&E include buildings, machinery, land, office equipment, furniture, and vehicles.


Highlights and Quick Summary

  • Property, Plant, Equpment (Net) for the quarter ending June 29, 2021 was $2.95 Million (a -6.88% decrease compared to previous quarter)
  • Year-over-year quarterly Property, Plant, Equpment (Net) decreased by -11.86%
  • Annual Property, Plant, Equpment (Net) for 2020 was $3.36 Million (a 140.62% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Property, Plant, Equpment (Net) of Phathom Pharmaceuticals, Inc.

Most recent Property, Plant, Equpment (Net)of PHAT including historical data for past 10 years.

Interactive Chart of Property, Plant, Equpment (Net) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Property, Plant, Equpment (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $2.95 $3.17
2020 $3.36 $3.35 $3.36 $0.77 $3.36
2019 $0.46 $0.04 $1.4

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.